Dendreon Corp. (DNDN). The biotechnology company forecast only modest sales growth for its Provenge prostate cancer vaccine for the next several quarters. It posted a net loss of $147.1 million, or $1.00 per share, compared with a loss of $79.3 million, or 56 cents per share, a year earlier.
DNDN is down 3.63 to 6.83 (34%)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment